Enrolling

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

J2A-MC-GZGS -

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.

Enter your city or zip code to find the nearest site

See if You May Qualify

Select a location and then answer a few questions or connect with the study site to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes, Overweight at Increased Cardiovascular Risk
What the trial is testing?
Orforglipron (LY3502970), Insulin Glargine
Could I receive a Placebo?
No
Enrollment Goal
2620
Trial Dates
Apr 3, 2023 - Dec 2025
How long will I be in the trial?
The study will last approximately 2 years may include up to 27 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have type 2 diabetes

  • Be taking a consistent dose of 1 to 3 diabetes drugs by mouth for the last 3 months

  • Be at high risk of heart or blood vessel diseases, or have kidney disease

  • Have high blood sugar as measured by hemoglobin A1C (HbA1c at least 7%)

Participants Must Not:

  • Have type 1 diabetes

  • Have history of an inflamed pancreas (pancreatitis)

  • Have history of an inflamed liver (hepatitis)

  • Have used any weight loss drugs, including herbal or nutritional supplements, within the last 3 months

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources